TOP TEN perturbations for 39431_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39431_at
Selected probe(set): 201455_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39431_at (201455_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.877634
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

esophageal squamous cell carcinoma study 1 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-2.4009457
Number of Samples:8 / 18
Experimental esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

phenobarbital study 3 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.3982906
Number of Samples:2 / 2
Experimental phenobarbital study 3 (10000uM)
Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

phenobarbital study 2 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.1287727
Number of Samples:2 / 2
Experimental phenobarbital study 2 (10000uM)
Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

esophageal adenocarcinoma study 1 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-1.9802818
Number of Samples:20 / 18
Experimental esophageal adenocarcinoma study 1
Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)

Relative Expression (log2-ratio):-1.9173422
Number of Samples:15 / 2
Experimental uterine/pelvic pathology study 2 (pro. MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)

Relative Expression (log2-ratio):-1.8325901
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):1.764741
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-1.6842117
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-1.682025
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.